India is home to the second-largest population of people with diabetes, and the numbers are rising steeply. Regular monitoring is critical, but existing solutions rely on invasive finger-prick methods or bulky devices, which cause pain, inconvenience, and poor compliance among patients. The lack of portable, user-friendly, and prick-free diagnostic solutions creates barriers for timely diabetes management and increases the risk of associated cardiovascular diseases.

Rahul and Neha Rastogi, both accomplished electronics engineers, have led major projects in global technology companies such as Samsung and CSC. Their entrepreneurial journey began with a personal crisis- Rahul’s father was hospitalized with chest discomfort and was found to be on the verge of a major heart attack. The angioplasty that followed, and the stress of frequent follow-up tests, left them wondering if heart monitoring could be made simpler, real-time, and more accessible. Putting their passion and purpose together, they built the pioneering SanketLife ECG device in 2015 (a portable, pocket-friendly, 12-lead ECG device), that won the Anjani Mashelkar Prize 2015. Since then, SanketLife device has recorded millions of ECGs across multiple countries, making timely heart monitoring available to people at scale.

Driven to make healthcare accessible anytime and anywhere, Rahul and Neha continued to innovate beyond the ECG device through their med-tech and software company, Agatsa. Their work has expanded into a suite of pocket-sized, easy-to-use healthcare monitoring solutions – one of them being a breakthrough non-invasive glucose monitoring device, EasyTouch Plus.

EasyTouch Plus is a non-invasive touch-based blood glucose monitoring device. By simply placing a finger on the device, users can obtain indicative glucose trend reading in under 15 seconds – without pricks or strips. The device is compact, highly portable, and enables regular monitoring anytime and anywhere. The device also provides a platform to track sugar readings over time, with no expiry or usage limits—making preventive care and monitoring simple, pain-free, and affordable. Unlike conventional wellness devices, EasyTouch Plus ensures high accuracy through calibration with glucose monitors. While eliminating pricks is a relief, EasyTouch Plus also proves remarkably affordable over time. Over the period of monitoring for an average diabetic person, EasyTouch Plus brings the effective cost down to just INR 0.25 (25 paise) per test—about 1/100th the cost of conventional monitoring – making lifelong diabetes care truly painless and affordable.

Since its launch in July 2025, over 12,000 EasyTouch Plus devices have already been sold through B2C channels, with demand continuing to rise. Agatsa is currently focused on the direct-to-consumer segment, making EasyTouch Plus easily accessible via online platforms, retail outlets, and pharmacies at an affordable price point. The company is now developing multi-patient versions of the device, that have potential to transform community healthcare. With these versions, Agatsa aims to expand into B2B partnerships with hospitals, diagnostic networks, and healthcare providers to integrate EasyTouch Plus into routine screenings and outpatient care at scale.